• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Adeno-associated virus enhances wild-type and oncolytic adenovirus spread.腺相关病毒可增强野生型和溶瘤腺病毒的传播。
Hum Gene Ther Methods. 2013 Dec;24(6):372-80. doi: 10.1089/hgtb.2013.124. Epub 2013 Oct 8.
2
HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.靶向肝癌的 HCCS1 基因修饰、四重调控溶瘤腺病毒作为一种肿瘤基因病毒治疗策略。
Mol Cancer. 2011 Nov 1;10:133. doi: 10.1186/1476-4598-10-133.
3
Tumor suppressor in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic adenovirus exerts specific antitumor actions in a mouse model.抑癌基因肺腺癌 1 型(TSLC1)介导的双调控溶瘤腺病毒在小鼠模型中发挥特异性抗肿瘤作用。
Acta Pharmacol Sin. 2013 Apr;34(4):531-40. doi: 10.1038/aps.2012.196. Epub 2013 Mar 18.
4
A vesicular stomatitis virus glycoprotein epitope-incorporated oncolytic adenovirus overcomes CAR-dependency and shows markedly enhanced cancer cell killing and suppression of tumor growth.一种掺入水泡性口炎病毒糖蛋白表位的溶瘤腺病毒克服了对嵌合抗原受体(CAR)的依赖性,并显示出显著增强的癌细胞杀伤能力和肿瘤生长抑制作用。
Oncotarget. 2015 Oct 27;6(33):34875-91. doi: 10.18632/oncotarget.5332.
5
A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.一种用于生成携带一个或两个转基因的溶瘤腺病毒载体的简化系统。
Cancer Gene Ther. 2008 Mar;15(3):173-82. doi: 10.1038/sj.cgt.7701105. Epub 2007 Dec 21.
6
Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.依托泊苷通过自上调多药耐药蛋白1(MDR1)启动子活性增强MDR1驱动的溶瘤腺病毒的抗肿瘤疗效。
Oncotarget. 2015 Nov 10;6(35):38308-26. doi: 10.18632/oncotarget.5702.
7
Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model.利用新型嵌合溶瘤腺病毒进行病毒治疗可延长人胰腺癌细胞异种移植模型的生存期。
Surgery. 2012 Sep;152(3):441-8. doi: 10.1016/j.surg.2012.05.040. Epub 2012 Jul 31.
8
Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.缺失胸苷激酶的痘苗病毒株Guang9的溶瘤效力
Oncotarget. 2017 Jun 20;8(25):40533-40543. doi: 10.18632/oncotarget.17125.
9
Double E1B 19 kDa- and E1B 55 kDa-deleted oncolytic adenovirus in combination with radiotherapy elicits an enhanced anti-tumor effect.双 E1B 19 kDa 和 E1B 55 kDa 缺失的溶瘤腺病毒联合放射治疗可增强抗肿瘤作用。
Gene Ther. 2009 Sep;16(9):1111-21. doi: 10.1038/gt.2009.72. Epub 2009 Jun 4.
10
Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.溶瘤腺病毒介导免疫核糖核酸酶的基因传递可增强抗癌活性。
Int J Cancer. 2015 May 1;136(9):2228-40. doi: 10.1002/ijc.29258. Epub 2014 Nov 12.

引用本文的文献

1
Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy.胶质母细胞瘤微环境及其通过溶瘤病毒疗法的重编程。
Front Cell Neurosci. 2022 Sep 9;16:819363. doi: 10.3389/fncel.2022.819363. eCollection 2022.
2
Designing and building oncolytic viruses.设计和构建溶瘤病毒。
Future Virol. 2017 Apr;12(4):193-213. doi: 10.2217/fvl-2016-0129. Epub 2017 Mar 31.
3
Oncolytic viruses: a new class of immunotherapy drugs.溶瘤病毒:一类新型免疫治疗药物。
Nat Rev Drug Discov. 2015 Sep;14(9):642-62. doi: 10.1038/nrd4663.
4
Persistent viremia by a novel parvovirus in a slow loris (Nycticebus coucang) with diffuse histiocytic sarcoma.一只患有弥漫性组织细胞肉瘤的懒猴(懒猴属)感染新型细小病毒后出现持续性病毒血症。
Front Microbiol. 2014 Dec 1;5:655. doi: 10.3389/fmicb.2014.00655. eCollection 2014.

本文引用的文献

1
Oncolytic virotherapy.溶瘤病毒疗法。
Nat Biotechnol. 2012 Jul 10;30(7):658-70. doi: 10.1038/nbt.2287.
2
Adenovirus i-leader truncation bioselected against cancer-associated fibroblasts to overcome tumor stromal barriers.针对癌症相关成纤维细胞选择的腺病毒 i 端截短体以克服肿瘤基质屏障。
Mol Ther. 2012 Jan;20(1):54-62. doi: 10.1038/mt.2011.159. Epub 2011 Aug 23.
3
Viral genome DNA/lipoplexes elicit in situ oncolytic viral replication and potent antitumor efficacy via systemic delivery.病毒基因组 DNA/脂质体通过全身给药引发原位溶瘤病毒复制和强大的抗肿瘤疗效。
J Control Release. 2011 Oct 30;155(2):317-25. doi: 10.1016/j.jconrel.2011.06.014. Epub 2011 Jun 14.
4
Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses.最小化 RB 反应性 E1A 启动子修饰以获得溶瘤腺病毒的效力、选择性和转基因武装能力。
Mol Ther. 2010 Nov;18(11):1960-71. doi: 10.1038/mt.2010.173. Epub 2010 Aug 31.
5
Cell carriers for oncolytic viruses: Fed Ex for cancer therapy.肿瘤溶瘤病毒的细胞载体:癌症治疗的“联邦快递”。
Mol Ther. 2009 Oct;17(10):1667-76. doi: 10.1038/mt.2009.194. Epub 2009 Aug 18.
6
Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function.重新设计腺病毒载体系统以实现基因功能的高通量分析。
Biotechniques. 2008 Dec;45(6):659-62, 664-8. doi: 10.2144/000112993.
7
Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency.对一种功能获得性突变进行生物筛选,该突变可增强腺病毒5型的释放并提高其抗肿瘤效力。
Cancer Res. 2008 Nov 1;68(21):8928-37. doi: 10.1158/0008-5472.CAN-08-1145.
8
In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses.通过腺相关病毒的多物种杂交和重新靶向进行体外和体内基因治疗载体的进化。
J Virol. 2008 Jun;82(12):5887-911. doi: 10.1128/JVI.00254-08. Epub 2008 Apr 9.
9
Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway.基于pRB途径的强效选择性溶瘤腺病毒ICOVIR-5的全身毒性-疗效概况
Mol Ther. 2007 Sep;15(9):1607-15. doi: 10.1038/sj.mt.6300239. Epub 2007 Jun 19.
10
Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy.载体细胞介导的具有复制能力的腺病毒用于癌症基因治疗的递送
Mol Ther. 2007 Jun;15(6):1121-8. doi: 10.1038/sj.mt.6300128. Epub 2007 Mar 27.

腺相关病毒可增强野生型和溶瘤腺病毒的传播。

Adeno-associated virus enhances wild-type and oncolytic adenovirus spread.

作者信息

Laborda Eduardo, Puig-Saus Cristina, Cascalló Manel, Chillón Miguel, Alemany Ramon

机构信息

1 Translational Research Laboratory, IDIBELL-Institut Català d'Oncologia , L'Hospitalet de Llobregat, 08907 Barcelona, Spain .

出版信息

Hum Gene Ther Methods. 2013 Dec;24(6):372-80. doi: 10.1089/hgtb.2013.124. Epub 2013 Oct 8.

DOI:10.1089/hgtb.2013.124
PMID:24020980
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3869535/
Abstract

The contamination of adenovirus (Ad) stocks with adeno-associated viruses (AAV) is usually unnoticed, and it has been associated with lower Ad yields upon large-scale production. During Ad propagation, AAV contamination needs to be detected routinely by polymerase chain reaction without symptomatic suspicion. In this study, we describe that the coinfection of either Ad wild type 5 or oncolytic Ad with AAV results in a large-plaque phenotype associated with an accelerated release of Ad from coinfected cells. This accelerated release was accompanied with the expected decrease in Ad yields in two out of three cell lines tested. Despite this lower Ad yield, coinfection with AAV accelerated cell death and enhanced the cytotoxicity mediated by Ad propagation. Intratumoral coinjection of Ad and AAV in two xenograft tumor models improved antitumor activity and mouse survival. Therefore, we conclude that accidental or intentional AAV coinfection has important implications for Ad-mediated virotherapy.

摘要

腺病毒(Ad)储备液被腺相关病毒(AAV)污染通常不易被察觉,并且与大规模生产时较低的Ad产量有关。在Ad繁殖过程中,需要通过聚合酶链反应常规检测AAV污染,而无需有症状怀疑。在本研究中,我们描述了Ad野生型5或溶瘤性Ad与AAV的共感染会导致大斑块表型,这与Ad从共感染细胞中加速释放有关。在测试的三个细胞系中的两个中,这种加速释放伴随着Ad产量的预期下降。尽管Ad产量较低,但与AAV的共感染加速了细胞死亡并增强了由Ad繁殖介导的细胞毒性。在两个异种移植肿瘤模型中瘤内共注射Ad和AAV提高了抗肿瘤活性并延长了小鼠存活时间。因此,我们得出结论,意外或有意的AAV共感染对Ad介导的病毒疗法具有重要意义。